Literature DB >> 20412788

Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.

Ji-Won Lee1, Yasuhiro Kobayashi, Yuko Nakamichi, Nobuyuki Udagawa, Naoyuki Takahashi, Nam-Kyung Im, Hwa-Jeong Seo, Won Bae Jeon, Takayuki Yonezawa, Byung-Yoon Cha, Je-Tae Woo.   

Abstract

Osteoclasts, bone-resorbing multinucleated cells, are differentiated from hemopoietic progenitors of the monocyte/macrophage lineage. Bone resorption by osteoclasts is considered a potential therapeutic target to the treatment of erosive bone diseases, including osteoporosis, rheumatoid arthritis, and periodontitis. In the present study, we found that alisol-B, a phyto-steroid from Alisma orientale Juzepczuk, exhibited inhibitory effects on osteoclastogenesis both in vitro and in vivo. Although RT-PCR analysis showed that alisol-B did not affect the 1alpha,25(OH)(2)D(3)-induced expressions of RANKL, OPG and M-CSF mRNAs in osteoblasts, addition of alisol-B to co-cultures of mouse bone marrow cells and primary osteoblasts with 10(-8)M 1alpha,25(OH)(2)D(3) caused significant inhibition of osteoclastogenesis. We further examined the direct effects of alisol-B on osteoclast precursors. Alisol-B strongly inhibited RANKL-induced osteoclast formation when added during the early stage of cultures, suggesting that alisol-B acts on osteoclast precursors to inhibit RANKL/RANK signaling. Among the RANK signaling pathways, alisol-B inhibited the phosphorylation of JNK, which are upregulated in response to RANKL in bone marrow macrophages, alisol-B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis. In addition, alisol-B suppressed the pit-forming activity and disrupted the actin ring formation of mature osteoclasts. In a hypercalcemic mouse model induced by 2-methylene-19-nor-(20S)-1alpha,25(OH)(2)D(3) (2MD), an analog of 1alpha,25(OH)(2)D(3), administration of alisol-B significantly suppressed 2MD-induced hypercalcemia as resulting from the inhibition of osteoclastogenesis. Taken together, these findings suggest that alisol-B may be a potential novel therapeutic molecule for bone disorders by targeting the differentiation of osteoclasts as well as their functions. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412788     DOI: 10.1016/j.bcp.2010.04.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Pharmacokinetic Profiling of Butylidenephthalide and Alisol B in Danggui-Shaoyao-San in Rats.

Authors:  Hui-Fei Wu; Xiang-Yu Wang; Ji-Feng Deng; Shi-Jian Quan; Qi Wang; Wei-Rong Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

2.  Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions.

Authors:  Mohammad Ahsanul Akbar; David Nardo; Mong-Jen Chen; Ahmed S Elshikha; Rubina Ahamed; Eslam M Elsayed; Claire Bigot; Lexie Shannon Holliday; Sihong Song
Journal:  Mol Med       Date:  2017-03-21       Impact factor: 6.354

Review 3.  Evolving Roles of Natural Terpenoids From Traditional Chinese Medicine in the Treatment of Osteoporosis.

Authors:  Yue Zhuo; Meng Li; Qiyao Jiang; Hanzhong Ke; Qingchun Liang; Ling-Feng Zeng; Jiansong Fang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-16       Impact factor: 6.055

4.  Inhibitory effects of osteoprotegerin on osteoclast formation and function under serum-free conditions.

Authors:  Ying-Xiao Fu; Jian-Hong Gu; Yi-Ran Zhang; Xi-Shuai Tong; Hong-Yan Zhao; Yan Yuan; Xue-Zhong Liu; Jian-Chun Bian; Zong-Ping Liu
Journal:  J Vet Sci       Date:  2013-06-30       Impact factor: 1.672

5.  Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.

Authors:  Moo Rim Kang; Sun Ah Jo; Yeo Dae Yoon; Ki Hwan Park; Soo Jin Oh; Jieun Yun; Chang Woo Lee; Ki-Hoan Nam; Youngsoo Kim; Sang-Bae Han; Jiyeon Yu; Jaerang Rho; Jong Soon Kang
Journal:  Mar Drugs       Date:  2014-11-24       Impact factor: 5.118

6.  The Korean herbal formulation Yukmijihwangtang stimulates longitudinal bone growth in animal models.

Authors:  Sung-Min Cho; Sun Haeng Lee; Donghun Lee; Ji Hong Lee; Gyu Tae Chang; Hocheol Kim; Jin Yong Lee
Journal:  BMC Complement Altern Med       Date:  2017-05-02       Impact factor: 3.659

7.  Leonurine Promotes the Osteoblast Differentiation of Rat BMSCs by Activation of Autophagy via the PI3K/Akt/mTOR Pathway.

Authors:  Bingkun Zhao; Qian Peng; Enoch Hin Lok Poon; Fubo Chen; Rong Zhou; Guangwei Shang; Dan Wang; Yuanzhi Xu; Raorao Wang; Shengcai Qi
Journal:  Front Bioeng Biotechnol       Date:  2021-02-23

8.  Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.

Authors:  Xiao-Lin Huang; Chao Liu; Xue-Mei Shi; Yu-Ting Cheng; Qian Zhou; Jian-Ping Li; Jian Liao
Journal:  Mol Med Rep       Date:  2021-12-22       Impact factor: 2.952

9.  Potential antiosteoporotic agents from plants: a comprehensive review.

Authors:  Min Jia; Yan Nie; Da-Peng Cao; Yun-Yun Xue; Jie-Si Wang; Lu Zhao; Khalid Rahman; Qiao-Yan Zhang; Lu-Ping Qin
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-31       Impact factor: 2.629

10.  Muscone Ameliorates Ovariectomy-Induced Bone Loss and Receptor Activator of Nuclear Factor-κb Ligand-Induced Osteoclastogenesis by Suppressing TNF Receptor-Associated Factor 6-Mediated Signaling Pathways.

Authors:  Xiao Zhai; Zijun Yan; Jian Zhao; Kai Chen; Yilin Yang; Mengxi Cai; Chen He; Chunyou Huang; Bo Li; Mingyuan Yang; Xiaoyi Zhou; Yingchuan Zhao; Xiaozhao Wei; Yushu Bai; Ming Li
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.